The counter has had a total traded volume of 34175 shares so far with a value of Rs 1.96 crore on the NSE. It traded at a price-to-earnings multiple of 14.0 and a price-to-book ratio of 1.59.
A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and reflects the price investors are willing to pay even for no growth in the business.
The scrip declined 20.73 per cent during the past one year, while the 30-share index advanced 9.82 per cent during the same period.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
Promoters held 48.76 per cent stake in the company as of 30-Jun-2022, while overseas investors and domestic institutional investors ownership stood at 20.71 per cent and 9.82 per cent, respectively.
The company reported consolidated sales of Rs 6276.54 crore for the quarter ended 30-Jun-2022, up 7.14 per cent from the previous quarter’s Rs 5858.25 crore and up 8.53 per cent from the year-ago quarter’s Rs 5783.29 crore.
Profit for the latest quarter stood at Rs 520.54 crore, down 32.39 per cent from the same quarter a year ago.